Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
| Image |  |
|---|---|
| Description | scientific article published on 19 September 2020 |
| Author/s |
author: Mark G. Lebwohl |
| Publication date | September 19, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |